Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 44.

Journal Article

Baues, C., Abety, N. A., Nast-Kolb, B. and Semrau, R. (2015). Local low-dose radiotherapy in two fractions as an effective treatment in patients with Mycosis fungoides. Strahlenther. Onkol., 191. S. S16 - 1. MUNICH: URBAN & VOGEL. ISSN 1439-099X

Baues, C., Marnitz, S., Engert, A., Baus, W., Jablonska, K., Fogliata, A., Vasquez-Torres, A., Scorsetti, M. and Cozzi, L. (2017). Proton versus Photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation. Strahlenther. Onkol., 193. S. S5 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Baues, C., Semrau, R., Gaipl, U. S., Broeckelmann, P. J., Rosenbrock, J., Engert, A. and Marnitz, S. (2017). Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma. Strahlenther. Onkol., 193 (2). S. 95 - 100. MUNICH: URBAN & VOGEL. ISSN 1439-099X

Borchmann, P., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Zijlstra, J. M., Huettmann, A., Markova, J., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M. and Engert, A. (2017). TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 24 - 26. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M. and Engert, A. (2020). Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Borchmann, S., Mueller, H., Haverkamp, H., Baues, C., Markova, J., Huettmann, A., Glunz, A., Fuchs, M., Borchmann, P. and Engert, A. (2016). OSTEONECROSIS AFTER TREATMENT FOR HODGKIN LYMPHOMA: THE GERMAN HODGKIN STUDY GROUP EXPERIENCE. Haematologica, 101. S. 62 - 63. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Borchmann, S., Mueller, H., Haverkamp, H., Baues, C., Markova, J., Huettmann, A., Glunz, A., Fuchs, M. and Engert, A. (2016). OSTEONECROSIS AS A TREATMENT COMPLICATION IN HODGKIN LYMPHOMA PATIENTS: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG). Haematologica, 101. S. 5 - 7. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Ceccon, G. S., Werner, J., Ruge, M., I, Goldbrunner, R., Celik, E., Baues, C., Deckert, M., Brunn, A., Buttner, R., Golla, H., Nogova, L., Schlamann, M., Kabbasch, C., Ruess, D., Hampl, J., Wollring, M., Bauer, E. K., Tscherpel, C., Fink, G. R., Langen, K. and Galldiks, N. (2022). Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors. Neuro-Oncology, 24. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866

Channaoui, M., Oertel, M., Kroeger, K., Baues, C., Haverkamp, U. and Eich, H. T. (2020). Investigation of the Dose Parameters as a Part of the Quality Assurance for the Hodgkin Study (HD17) and its Consequences on the Tumor Control Rate and the Rate of Side Effects. Strahlenther. Onkol., 196 (SUPPL 1). S. S166 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Daniel, R., Hamisch, C., Grau, S., Jablonska, K., Baues, C., Kocher, M., Treuer, H. and Ruge, M. (2018). HYPOFRACTIONATED RADIOSURGERY FOR BENIGN SKULL BASE TUMORS. Neuro-Oncology, 20. S. 311 - 312. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866

Dietlein, M., Kuhnert, G., Semrau, R., Nast-Kolb, B., Baues, C., Fuchs, M., Drzezga, A. and Kobe, C. (2014). Current importance of positron emission tomography in Hodgkin's lymphoma. Onkologe, 20 (5). S. 429 - 439. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Eich, H. T., Kriz, J., Engenhart-Cabillic, R., Haverkamp, U., Herfarth, K., Lukas, P., Schmidberger, H., Staar, S., Pluetschow, A., Fuchs, M., Engert, A. and Baues, C. (2016). FINAL RESULTS OF A QUALITY ASSURANCE PROGRAM WITHIN THE GERMAN HODGKIN STUDY GROUP HD13/14 TRIAL - A REPORT FROM THE RADIOTHERAPY REFERENCE PANEL INTEGRATING MODERN GUIDELINES. Haematologica, 101. S. 14 - 15. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Eich, H. T., Kriz, J., Reinartz, G., Kobe, C., Kuhnert, G., Haverkamp, U., Haverkamp, H., Hegerfeld, K., Baues, C. and Engert, A. (2013). Relapse Analysis After Radiation Therapy of PET-Positive Residual Tumors of Patients With Advanced Stage Hodgkin Lymphoma Treated in the HD15 Trial of the German Hodgkin Study Group (GHSG). Int. J. Radiat. Oncol. Biol. Phys., 87 (2). S. S5 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X

Eichenauer, D. A., Kreissl, S., Buehnen, I., Baues, C., Kobe, C., van Heek, L., Goergen, H., Fuchs, M., Hartmann, S., von Tresckow, B., Engert, A. and Borchmann, P. (2021). PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study. Ann. Oncol., 32 (6). S. 807 - 811. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Jakob, T., Follmann, M., Borchmann, P., Baues, C., Sasse, S., Broeckelmann, P. J., Kreissl, S., Eichenauer, D., von Tresckow, B., Buerkle, C., Engert, A. and Skoetz, N. (2018). Guideline update on diagnosis, therapy and follow-up of adult Hodgkin lymphoma patients. Oncol. Res. Treat., 41. S. 17 - 18. BASEL: KARGER. ISSN 2296-5262

Kloock, L., Semrau, R., Baues, C., Kocher, M., Kunze, S. and Marnitz, S. (2017). PSMA-PET/CT guided hypofractionated robotic radiosurgery of local lymph node relapse of prostate cancer: initial report. Strahlenther. Onkol., 193. S. S139 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Kobe, C., Goergen, H., Fuchs, M., Eich, H. T., Baues, C., Diehl, V., Kuhnert, G., Drzezga, A., Dietlein, M., Engert, A. and Borchmann, P. (2017). Treatment Reduction in Patients with Advanced-Stage Hodgkin Lymphoma and Negative Interim FDG-PET: Final Results of the International, Randomized, Phase 3 HD18 Trial by the German Hodgkin Study Group. Eur. J. Nucl. Med. Mol. Imaging, 44. S. S312 - 1. NEW YORK: SPRINGER. ISSN 1619-7089

Kobe, C., Kuhnert, G., Haverkamp, H., Fuchs, M., Kahraman, D., Eich, H. -T., Kriz, J., Baues, C., Nast-Kolb, B., Broeckelmann, P. J., Borchmann, P., Drzezga, A., Engert, A. and Dietlein, M. (2015). Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma. Nuklearmedizin, 54 (6). S. 241 - 247. STUTTGART: GEORG THIEME VERLAG KG. ISSN 2567-6407

Kreissl, S., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Huettmann, A., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M., Engert, A. and Borchmann, P. (2017). Treatment reduction in patients with advanced-stage-Hodgkin-lymphoma and negative interim PET: final results of the international randomized phase 3 trial HD18 by the German Hodgkin Study Goup. Oncol. Res. Treat., 40. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262

Kriz, J., Baues, C., Engenhart-Cabillic, R., Haverkamp, U., Herfart, K., Lukas, P., Pluetschow, A., Schmidberger, H., Staar, S., Fuchs, M., Engert, A. and Eich, H. T. (2017). Quality control of involved field radiotherapy in the HD 13 and HD 14 trials. Strahlenther. Onkol., 193 (2). S. 109 - 116. MUNICH: URBAN & VOGEL. ISSN 1439-099X

Kriz, J., Baues, C., Engenhart-Cabillic, R., Haverkamp, U., Herfarth, K., Lukas, P., Schmidberger, H., Marnitz-Schulze, S., Fuchs, M., Engert, A. and Eich, H. T. (2017). New quality assurance program integrating modern radiotherapy within the German Hodgkin Study Group. Strahlenther. Onkol., 193 (2). S. 100 - 109. MUNICH: URBAN & VOGEL. ISSN 1439-099X

Kriz, J., Baues, C., Oertel, M., Engenhart-Cabillic, R., Herfarth, K., Lukas, P., Marnitz-Schulze, S., Schmidberger, H., Vordermark, D., Haverkamp, U., Engert, A. and Eich, H. (2018). First Results of Quality Control of Involved Node Radiotherapy within the HD17-Study of the German Hodgkin Study Group (GHSG). Strahlenther. Onkol., 194. S. S14 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Kriz, J., Pluetschow, A., Engenhart-Cabillic, R., Herfarth, K., Lukas, P., Schmidberger, H., Staar, S., Haverkamp, U., Baues, C., Engert, A. and Eich, H. (2015). Analysis of the Quality Assurance Program of the Involved Field Radiotherapy within the HD13 and HD14 Study the German Hodgkin Study Group. Strahlenther. Onkol., 191. S. S10 - 2. MUNICH: URBAN & VOGEL. ISSN 1439-099X

Kriz, J., Pluetschow, A., Engenhart-Cabillic, R., Herfarth, K. K., Lukas, P., Schmidberger, H., Staar, S., Haverkamp, U., Baues, C., Engert, A. and Eich, H. (2015). Quality Assurance of Involved Field Radiation Therapy Within the HD13 and HD14 Trial (early stages) of the German Hodgkin Study Group. Int. J. Radiat. Oncol. Biol. Phys., 93 (3). S. E449 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X

Kunze, D. E., Baues, C., Semrau, R., Kocher, M., Ngum, A. and Marnitz-Schulze, S. (2016). Retrospective Study on Re-Irradiation of ENT Recurrence Tumor, Evaluation of Tolerability, the local Control and the Overall Survival. Strahlenther. Onkol., 192. S. 124 - 126. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Linde, P., Baues, C., Marnitz, S., Rosenbrock, J., Celik, E., Quaas, A., Fischer, T., Schomaecker, K., Drzezga, A., Wester, H. -J and Kobe, C. (2020). (68) Ga-Pentixafor-PET/CT-based Radiation Planning in Patients with Esophageal Cancer. Strahlenther. Onkol., 196 (SUPPL 1). S. S149 - 2. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Oertel, M., Elsayad, K., Engenhart-Cabillic, R., Reinartz, G., Baues, C., Schmidberger, H., Vordermark, D., Marnitz, S., Lukas, P., Ruebe, C., Engert, A., Lenz, G. and Eich, H. T. (2020). Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance. Strahlenther. Onkol., 196 (12). S. 1096 - 1103. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Ostheimer, C., Baues, C., Baumann, R., Billiet, C., Dobiasch, S., Ebert, N., Fleischmann, D., Gauer, T., Goy, Y., Haussmann, J., Henkenberens, C., Kaessmann, L., Lopez Guerra, J., Kaul, D., Krug, D., Maeurer, M., Niyazi, M., Oertel, M., Panje, C., Sautter, L., Schmitt, D., Suess, C., Trommer-Nestler, M., Ziegler, S. and Medenwald, D. (2018). Predictive value of GTV in radiotherapy of NSCLC - early results of the NCT03055715 trial. Radiother. Oncol., 127. S. S175 - 1. CLARE: ELSEVIER IRELAND LTD. ISSN 1879-0887

Ostheimer, C., Baues, C., Baumann, R., Billiet, C., Dobiasch, S., Ebert, N., Fleischmann, D. F., Gauer, T., Giordano, F., Goy, Y., Hausmann, J., Henkenberens, C., Kaesmann, L., Guerra, Lopez J. L., Kaul, D., Krug, D., M, Maeurer, Niyazi, M., Oertel, M., Panje, C. M., Pyschny, F., Schmitt, D., Sautter, L., Suess, C., Thieme, A. H., Trommer-Nestler, M., Ziegler, S. and Medenwald, D. (2018). Acute toxicity in the radical radiotherapy of advanced NSCLC-results of the NCT03055715 trial of the yDEGRO Trial Group. Strahlenther. Onkol., 194. S. S139 - 2. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Ostheimer, C., Baues, C., Baumann, R., Billiet, C., Dobiasch, S., Ebert, N., Fleischmann, D. F., Gauer, T., Giordano, F., Goy, Y., Hausmann, J., Henkenberens, C., Kaesmann, L., Guerra, Lopez J. L., Kaul, D., Krug, D., Maeurer, M., Niyazi, M., Oertel, M., Panje, C. M., Pyschny, F., Schmitt, D., Sautter, L., Suess, C., Thieme, A. H., Trommer-Nestler, M., Ziegler, S. and Medenwald, D. (2018). Prognostic and predictive value of GTV in the radical radiotherapy of advanced NSCLC-early results of the NCT03055715 trial of the yDEGRO Trial Group. Strahlenther. Onkol., 194. S. S23 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Ostheimer, C., Baues, C., Baumann, R., Dobiasch, S., Eze, C., Fleischmann, D., Gauer, T., Giordano, F. A., Goy, Y., Hausmann, J., Henkenberens, C., Kaul, D. P., Kloock, L., Krug, D., Kaesmann, L., Niyazi, K-M., Maeurer, M., Oertel, M., Panje, C., Rosenbrock, J., Sautter, L., Schmitt, D., Suess, C., Thieme, A. H., Trommer-Nestler, M., Ziegler, S., Ebert, N. and Medenwald, D. (2018). Prognostic relevance of tumor volume and its changes in the radical radiotherapy of advanced NSCLC - a multicenter retrospective evaluation of the working group young DEGRO of the German Society of Radiation Oncology (DEGRO). Oncol. Res. Treat., 41. S. 106 - 107. BASEL: KARGER. ISSN 2296-5262

Ostheimer, C., Maeurer, M., Ebert, N., Schmitt, D., Krug, D., Baumann, R., Henkenberens, C., Giordano, F. A., Sautter, L., Lopez, Guerra, Fleischmann, D. F., Niyazi, M., Kaesmann, L., Kaul, D., Thieme, A. H., Billiet, C., Dobiasch, S., Arnold, C. R., Oertel, M., Haussmann, J., Gauer, T., Goy, Y., Suess, C., Ziegler, S., Panje, C. M., Baues, C., Trommer, M., Skripcak, T. and Medenwald, D. (2021). Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group (Jan, 10.1007/s00066-020-01727-4, 2021). Strahlenther. Onkol., 197 (6). S. 560 - 562. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Ostheimer, C., Maeurer, M., Ebert, N., Schmitt, D., Krug, D., Baumann, R., Henkenberens, C., Giordano, F. A., Sautter, L., Lopez, Guerra, Fleischmann, D. F., Niyazi, M., Kasmann, L., Kaul, D., Thieme, A. H., Billiet, C., Dobiasch, S., Arnold, C. R., Oertel, M., Haussmann, J., Gauer, T., Goy, Y., Suess, C., Ziegler, S., Panje, C. M., Baues, C., Trommer-Nestler, M., Skripcak, T. and Medenwald, D. (2021). Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. Strahlenther. Onkol., 197 (5). S. 385 - 396. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Rosenbrock, J., Goergen, H., Semrau, R., Nast-Kolb, B., Celik, E., Morgenthaler, J., Assenmacher, K., Houbois, C., Engert, A., Baues, C. and Marnitz, S. (2017). Volumetric assessment of mediastinal masses in Hodgkin Lymphoma - leaving history behind and approaching the truth. Strahlenther. Onkol., 193. S. S127 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Sasse, S., Broeckelmann, P. J., Baues, C., Eich, H. T. and Engert, A. (2018). Treatment of early stage Hodgkin lymphoma. Discussion of current trials and treatment recommendations. Onkologe, 24 (4). S. 303 - 315. NEW YORK: SPRINGER. ISSN 1433-0415

Sasse, S., Momotow, J., Broeckelmann, P. J., Baues, C., Eich, H. T. and Engert, A. (2022). Treatment of early stage favorable and unfavorable Hodgkin lymphoma. Onkologie, 28 (10). S. 879 - 889. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234

Semrau, R., Kocher, M., Temming, S., Baues, C., Brendemuehl, A., Baus, W. and Marnitz-Schulze, S. (2016). Stereotactic body radiation therapy (SBRT) for liver metastases in oligometastatic patients treated with the CyberKnife (R) system. Strahlenther. Onkol., 192. S. 97 - 98. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Stippel, D. L., Wahba, R., Bruns, C. J., Bunck, A., Baues, C. and Persigehl, T. (2018). Image-guided, minimally invasive surgery and other local therapeutic procedures for primary liver tumors. Chirurg, 89 (11). S. 872 - 880. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0385

Theurich, S., Rothschild, S. I., Hoffmann, M., Fabri, M., Sommer, A., Marquez, M. Garcia, Thelen, M., Schill, C., Merki, R., Schmid, T., Koeberle, D., Zippelius, A., Baues, C., Mauch, C., Tigges, C., Kreuter, A., von Bergwelt-Baildon, M. and Schlaak, M. (2016). Cytotoxic local tumor treatment in combination with xystemic Ipilimumab enhances the efficacy of this immunotherapy and prolongs overall survival in patients with advanced malignant melanoma. Oncol. Res. Treat., 39. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262

Theurich, S., Rothschild, S., I, Hoffmann, M., Fabri, M., Sommer, A., Garcia-Marquez, M., Thelen, M., Schill, C., Merki, R., Schmid, T., Koeberle, D., Zippelius, A., Baues, C., Mauch, C., Tigges, C., Kreuter, A., Borggrefe, J., Schlaak, M. and von Bergwelt-Baildon, M. (2016). Local treatment of tumors or metastases in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Oncol. Res. Treat., 39. S. 103 - 105. BASEL: KARGER. ISSN 2296-5262

Trommer-Nestler, M., Baues, C., Ruge, M., Schlaak, M., Ruess, D., Jablonska, K., Kocher, M., Semrau, R. and Marnitz, S. (2017). Radiosurgery in melanoma patients with brain metastases under ongoing anti-PD-1 treatment. Strahlenther. Onkol., 193. S. S14 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Trommer-Nestler, M., Yeo, S. Y., Marnitz, S., Persigehl, T., Bunck, A., Schlaak, M., Gruell, H., Theurich, S., von Bergwelt-Baildon, M., Herter, J., Celik, E., Rosenbrock, J. and Baues, C. (2018). Abscopal effects in metastasized cancer patients treated with PD-1 inhibition and radiation therapy. Strahlenther. Onkol., 194. S. S200 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Voltin, C., Stockter, S., Baues, C., Fuchs, M., Dietlein, M., Mettler, J., Engert, A., Borchmann, P., Drzezga, A. and Kobe, C. (2017). Staging Patients with Hodgkin Lymphoma - Is Bone Marrow Biopsy Still Necessary in the Era of F-18-FDG PET? Eur. J. Nucl. Med. Mol. Imaging, 44. S. S244 - 2. NEW YORK: SPRINGER. ISSN 1619-7089

Voltin, C. -A., Goergen, H., Baues, C., Fuchs, M., Mettler, J., Kreissl, S., Oertl, J., Klaeser, B., Moccia, A., Drzezga, A., Engert, A., Borchmann, P., Dietlein, M. and Kobe, C. (2018). Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Ann. Oncol., 29 (9). S. 1926 - 1932. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

This list was generated on Fri Mar 29 13:05:35 2024 CET.